Global Synthetic Cannabinoids Market

Synthetic Cannabinoids Comprehensive Study by Type (Classical Cannabinoids, Non-Classical Cannabinoids, Hybrid Cannabinoids, Aminoalkylindoles, Eicosanoids), Application (Healthcare, Personal Care, Others), Sales Channel (Direct, Indirect) Players and Region - Global Market Outlook to 2026

Synthetic Cannabinoids Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Synthetic Cannabinoids Market Scope?
Synthetic cannabinoids are a category of molecules that bind to constant receptors to which cannabinoids (THC and CBD) in cannabis plants attach. They are designer medicine, usually sprayed onto plant matter, and are typically Smoked up, though they need conjointly been Consumed as a targeted liquid form. They have been marketed as herbal incense, or "herbal smoking blends", and sold-out underneath common names like K2, Spice, and artificial Marijuana. They’re typically labeled "not for human consumption" for liability defense.

The Synthetic Cannabinoids market study is being classified by Type (Classical Cannabinoids, Non-Classical Cannabinoids, Hybrid Cannabinoids, Aminoalkylindoles and Eicosanoids), by Application (Healthcare, Personal Care and Others) and major geographies with country level break-up.

Noramco (United States), Lygos (Librede) (United States), CV Sciences (United States), Hyasynth Biologicals (Canada), Renew Biopharma (United States), CannBioRx Life Sciences (United States), Ginkgo Bioworks (United States), AbbVie Inc. (United States), GW Pharmaceuticals plc (United Kingdom) and Mylan N.V. (United States) are some of the key players profiled in the study. Additionally, the Vendors which are also part of the research are Isodiol International Inc (Canada), CURE Pharmaceutical (United States), Zynerba Pharmaceuticals, Inc. (United States), Aphios Corporation (United Kingdom), Botanix Pharmaceuticals (Australia) and Insys Therapeutics, Inc (United States).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Synthetic Cannabinoids market by Type, Application and Region.

On the basis of geography, the market of Synthetic Cannabinoids has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Influencers and their development strategies
In 2020, Lygos, Inc., a full-stack supplier of sustainable specialty chemicals that deliver high-value performance without environmental toxicity, proclaimed the acquisition of Librede, Inc., an associate rising artificial biology company that targeted cannabinoid products for the buyer market. The combined platforms modify Lygos for the rapid growth of high quality, property, and rare cannabinoids and quickly commercialize new innovative cannabinoid-based Consumer, nutraceutical, and pharmaceutical product range.

United Kingdom: The UK controls synthetic cannabinoids by analog under the Misuse of Drugs Act, 1971 as Class B drugs. and United States: Synthetic Drug Abuse Prevention Act of 2012 banned synthetic compounds commonly found in synthetic marijuana.

Influencing Market Trend
  • The Demand for Artificial Cannabinoids to Assess the Potential Impact to Treat a Spread of Diseases and Symptoms

Market Drivers
  • Rising Consumer Interest and Demand for Non-Regulated Psychotropic Drug

Opportunities
  • Neurodegenerative Diseases, Pain Suppressors And Cancer

Restraints
  • Stringent Government Rules and Regulation Regarding Cannabis Possession and Usage

Challenges
  • Transportation of Non-Essential Goods with No Raw Use Benefits and Commodities
  • Side Effects of Synthetic Cannabinoids


Key Target Audience
Synthetic Cannabinoids Manufacturer, Trader/Supplier/Distributors, Health Institutes, Research Institutes, Government Bodies and Others

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • Classical Cannabinoids
  • Non-Classical Cannabinoids
  • Hybrid Cannabinoids
  • Aminoalkylindoles
  • Eicosanoids
By Application
  • Healthcare
  • Personal Care
  • Others
By Sales Channel
  • Direct
  • Indirect

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Consumer Interest and Demand for Non-Regulated Psychotropic Drug
    • 3.3. Market Challenges
      • 3.3.1. Transportation of Non-Essential Goods with No Raw Use Benefits and Commodities
      • 3.3.2. Side Effects of Synthetic Cannabinoids
    • 3.4. Market Trends
      • 3.4.1. The Demand for Artificial Cannabinoids to Assess the Potential Impact to Treat a Spread of Diseases and Symptoms
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Synthetic Cannabinoids, by Type, Application, Sales Channel and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Synthetic Cannabinoids (Value)
      • 5.2.1. Global Synthetic Cannabinoids by: Type (Value)
        • 5.2.1.1. Classical Cannabinoids
        • 5.2.1.2. Non-Classical Cannabinoids
        • 5.2.1.3. Hybrid Cannabinoids
        • 5.2.1.4. Aminoalkylindoles
        • 5.2.1.5. Eicosanoids
      • 5.2.2. Global Synthetic Cannabinoids by: Application (Value)
        • 5.2.2.1. Healthcare
        • 5.2.2.2. Personal Care
        • 5.2.2.3. Others
      • 5.2.3. Global Synthetic Cannabinoids by: Sales Channel (Value)
        • 5.2.3.1. Direct
        • 5.2.3.2. Indirect
      • 5.2.4. Global Synthetic Cannabinoids Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Synthetic Cannabinoids: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Noramco (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Lygos (Librede) (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. CV Sciences (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Hyasynth Biologicals (Canada)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Renew Biopharma (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. CannBioRx Life Sciences (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Ginkgo Bioworks (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. AbbVie Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. GW Pharmaceuticals plc (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Mylan N.V. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Synthetic Cannabinoids Sale, by Type, Application, Sales Channel and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Synthetic Cannabinoids (Value)
      • 7.2.1. Global Synthetic Cannabinoids by: Type (Value)
        • 7.2.1.1. Classical Cannabinoids
        • 7.2.1.2. Non-Classical Cannabinoids
        • 7.2.1.3. Hybrid Cannabinoids
        • 7.2.1.4. Aminoalkylindoles
        • 7.2.1.5. Eicosanoids
      • 7.2.2. Global Synthetic Cannabinoids by: Application (Value)
        • 7.2.2.1. Healthcare
        • 7.2.2.2. Personal Care
        • 7.2.2.3. Others
      • 7.2.3. Global Synthetic Cannabinoids by: Sales Channel (Value)
        • 7.2.3.1. Direct
        • 7.2.3.2. Indirect
      • 7.2.4. Global Synthetic Cannabinoids Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Synthetic Cannabinoids: by Type(USD Million)
  • Table 2. Synthetic Cannabinoids Classical Cannabinoids , by Region USD Million (2015-2020)
  • Table 3. Synthetic Cannabinoids Non-Classical Cannabinoids , by Region USD Million (2015-2020)
  • Table 4. Synthetic Cannabinoids Hybrid Cannabinoids , by Region USD Million (2015-2020)
  • Table 5. Synthetic Cannabinoids Aminoalkylindoles , by Region USD Million (2015-2020)
  • Table 6. Synthetic Cannabinoids Eicosanoids , by Region USD Million (2015-2020)
  • Table 7. Synthetic Cannabinoids: by Application(USD Million)
  • Table 8. Synthetic Cannabinoids Healthcare , by Region USD Million (2015-2020)
  • Table 9. Synthetic Cannabinoids Personal Care , by Region USD Million (2015-2020)
  • Table 10. Synthetic Cannabinoids Others , by Region USD Million (2015-2020)
  • Table 11. Synthetic Cannabinoids: by Sales Channel(USD Million)
  • Table 12. Synthetic Cannabinoids Direct , by Region USD Million (2015-2020)
  • Table 13. Synthetic Cannabinoids Indirect , by Region USD Million (2015-2020)
  • Table 14. South America Synthetic Cannabinoids, by Country USD Million (2015-2020)
  • Table 15. South America Synthetic Cannabinoids, by Type USD Million (2015-2020)
  • Table 16. South America Synthetic Cannabinoids, by Application USD Million (2015-2020)
  • Table 17. South America Synthetic Cannabinoids, by Sales Channel USD Million (2015-2020)
  • Table 18. Brazil Synthetic Cannabinoids, by Type USD Million (2015-2020)
  • Table 19. Brazil Synthetic Cannabinoids, by Application USD Million (2015-2020)
  • Table 20. Brazil Synthetic Cannabinoids, by Sales Channel USD Million (2015-2020)
  • Table 21. Argentina Synthetic Cannabinoids, by Type USD Million (2015-2020)
  • Table 22. Argentina Synthetic Cannabinoids, by Application USD Million (2015-2020)
  • Table 23. Argentina Synthetic Cannabinoids, by Sales Channel USD Million (2015-2020)
  • Table 24. Rest of South America Synthetic Cannabinoids, by Type USD Million (2015-2020)
  • Table 25. Rest of South America Synthetic Cannabinoids, by Application USD Million (2015-2020)
  • Table 26. Rest of South America Synthetic Cannabinoids, by Sales Channel USD Million (2015-2020)
  • Table 27. Asia Pacific Synthetic Cannabinoids, by Country USD Million (2015-2020)
  • Table 28. Asia Pacific Synthetic Cannabinoids, by Type USD Million (2015-2020)
  • Table 29. Asia Pacific Synthetic Cannabinoids, by Application USD Million (2015-2020)
  • Table 30. Asia Pacific Synthetic Cannabinoids, by Sales Channel USD Million (2015-2020)
  • Table 31. China Synthetic Cannabinoids, by Type USD Million (2015-2020)
  • Table 32. China Synthetic Cannabinoids, by Application USD Million (2015-2020)
  • Table 33. China Synthetic Cannabinoids, by Sales Channel USD Million (2015-2020)
  • Table 34. Japan Synthetic Cannabinoids, by Type USD Million (2015-2020)
  • Table 35. Japan Synthetic Cannabinoids, by Application USD Million (2015-2020)
  • Table 36. Japan Synthetic Cannabinoids, by Sales Channel USD Million (2015-2020)
  • Table 37. India Synthetic Cannabinoids, by Type USD Million (2015-2020)
  • Table 38. India Synthetic Cannabinoids, by Application USD Million (2015-2020)
  • Table 39. India Synthetic Cannabinoids, by Sales Channel USD Million (2015-2020)
  • Table 40. South Korea Synthetic Cannabinoids, by Type USD Million (2015-2020)
  • Table 41. South Korea Synthetic Cannabinoids, by Application USD Million (2015-2020)
  • Table 42. South Korea Synthetic Cannabinoids, by Sales Channel USD Million (2015-2020)
  • Table 43. Taiwan Synthetic Cannabinoids, by Type USD Million (2015-2020)
  • Table 44. Taiwan Synthetic Cannabinoids, by Application USD Million (2015-2020)
  • Table 45. Taiwan Synthetic Cannabinoids, by Sales Channel USD Million (2015-2020)
  • Table 46. Australia Synthetic Cannabinoids, by Type USD Million (2015-2020)
  • Table 47. Australia Synthetic Cannabinoids, by Application USD Million (2015-2020)
  • Table 48. Australia Synthetic Cannabinoids, by Sales Channel USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Synthetic Cannabinoids, by Type USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Synthetic Cannabinoids, by Application USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Synthetic Cannabinoids, by Sales Channel USD Million (2015-2020)
  • Table 52. Europe Synthetic Cannabinoids, by Country USD Million (2015-2020)
  • Table 53. Europe Synthetic Cannabinoids, by Type USD Million (2015-2020)
  • Table 54. Europe Synthetic Cannabinoids, by Application USD Million (2015-2020)
  • Table 55. Europe Synthetic Cannabinoids, by Sales Channel USD Million (2015-2020)
  • Table 56. Germany Synthetic Cannabinoids, by Type USD Million (2015-2020)
  • Table 57. Germany Synthetic Cannabinoids, by Application USD Million (2015-2020)
  • Table 58. Germany Synthetic Cannabinoids, by Sales Channel USD Million (2015-2020)
  • Table 59. France Synthetic Cannabinoids, by Type USD Million (2015-2020)
  • Table 60. France Synthetic Cannabinoids, by Application USD Million (2015-2020)
  • Table 61. France Synthetic Cannabinoids, by Sales Channel USD Million (2015-2020)
  • Table 62. Italy Synthetic Cannabinoids, by Type USD Million (2015-2020)
  • Table 63. Italy Synthetic Cannabinoids, by Application USD Million (2015-2020)
  • Table 64. Italy Synthetic Cannabinoids, by Sales Channel USD Million (2015-2020)
  • Table 65. United Kingdom Synthetic Cannabinoids, by Type USD Million (2015-2020)
  • Table 66. United Kingdom Synthetic Cannabinoids, by Application USD Million (2015-2020)
  • Table 67. United Kingdom Synthetic Cannabinoids, by Sales Channel USD Million (2015-2020)
  • Table 68. Netherlands Synthetic Cannabinoids, by Type USD Million (2015-2020)
  • Table 69. Netherlands Synthetic Cannabinoids, by Application USD Million (2015-2020)
  • Table 70. Netherlands Synthetic Cannabinoids, by Sales Channel USD Million (2015-2020)
  • Table 71. Rest of Europe Synthetic Cannabinoids, by Type USD Million (2015-2020)
  • Table 72. Rest of Europe Synthetic Cannabinoids, by Application USD Million (2015-2020)
  • Table 73. Rest of Europe Synthetic Cannabinoids, by Sales Channel USD Million (2015-2020)
  • Table 74. MEA Synthetic Cannabinoids, by Country USD Million (2015-2020)
  • Table 75. MEA Synthetic Cannabinoids, by Type USD Million (2015-2020)
  • Table 76. MEA Synthetic Cannabinoids, by Application USD Million (2015-2020)
  • Table 77. MEA Synthetic Cannabinoids, by Sales Channel USD Million (2015-2020)
  • Table 78. Middle East Synthetic Cannabinoids, by Type USD Million (2015-2020)
  • Table 79. Middle East Synthetic Cannabinoids, by Application USD Million (2015-2020)
  • Table 80. Middle East Synthetic Cannabinoids, by Sales Channel USD Million (2015-2020)
  • Table 81. Africa Synthetic Cannabinoids, by Type USD Million (2015-2020)
  • Table 82. Africa Synthetic Cannabinoids, by Application USD Million (2015-2020)
  • Table 83. Africa Synthetic Cannabinoids, by Sales Channel USD Million (2015-2020)
  • Table 84. North America Synthetic Cannabinoids, by Country USD Million (2015-2020)
  • Table 85. North America Synthetic Cannabinoids, by Type USD Million (2015-2020)
  • Table 86. North America Synthetic Cannabinoids, by Application USD Million (2015-2020)
  • Table 87. North America Synthetic Cannabinoids, by Sales Channel USD Million (2015-2020)
  • Table 88. United States Synthetic Cannabinoids, by Type USD Million (2015-2020)
  • Table 89. United States Synthetic Cannabinoids, by Application USD Million (2015-2020)
  • Table 90. United States Synthetic Cannabinoids, by Sales Channel USD Million (2015-2020)
  • Table 91. Canada Synthetic Cannabinoids, by Type USD Million (2015-2020)
  • Table 92. Canada Synthetic Cannabinoids, by Application USD Million (2015-2020)
  • Table 93. Canada Synthetic Cannabinoids, by Sales Channel USD Million (2015-2020)
  • Table 94. Mexico Synthetic Cannabinoids, by Type USD Million (2015-2020)
  • Table 95. Mexico Synthetic Cannabinoids, by Application USD Million (2015-2020)
  • Table 96. Mexico Synthetic Cannabinoids, by Sales Channel USD Million (2015-2020)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Synthetic Cannabinoids: by Type(USD Million)
  • Table 108. Synthetic Cannabinoids Classical Cannabinoids , by Region USD Million (2021-2026)
  • Table 109. Synthetic Cannabinoids Non-Classical Cannabinoids , by Region USD Million (2021-2026)
  • Table 110. Synthetic Cannabinoids Hybrid Cannabinoids , by Region USD Million (2021-2026)
  • Table 111. Synthetic Cannabinoids Aminoalkylindoles , by Region USD Million (2021-2026)
  • Table 112. Synthetic Cannabinoids Eicosanoids , by Region USD Million (2021-2026)
  • Table 113. Synthetic Cannabinoids: by Application(USD Million)
  • Table 114. Synthetic Cannabinoids Healthcare , by Region USD Million (2021-2026)
  • Table 115. Synthetic Cannabinoids Personal Care , by Region USD Million (2021-2026)
  • Table 116. Synthetic Cannabinoids Others , by Region USD Million (2021-2026)
  • Table 117. Synthetic Cannabinoids: by Sales Channel(USD Million)
  • Table 118. Synthetic Cannabinoids Direct , by Region USD Million (2021-2026)
  • Table 119. Synthetic Cannabinoids Indirect , by Region USD Million (2021-2026)
  • Table 120. South America Synthetic Cannabinoids, by Country USD Million (2021-2026)
  • Table 121. South America Synthetic Cannabinoids, by Type USD Million (2021-2026)
  • Table 122. South America Synthetic Cannabinoids, by Application USD Million (2021-2026)
  • Table 123. South America Synthetic Cannabinoids, by Sales Channel USD Million (2021-2026)
  • Table 124. Brazil Synthetic Cannabinoids, by Type USD Million (2021-2026)
  • Table 125. Brazil Synthetic Cannabinoids, by Application USD Million (2021-2026)
  • Table 126. Brazil Synthetic Cannabinoids, by Sales Channel USD Million (2021-2026)
  • Table 127. Argentina Synthetic Cannabinoids, by Type USD Million (2021-2026)
  • Table 128. Argentina Synthetic Cannabinoids, by Application USD Million (2021-2026)
  • Table 129. Argentina Synthetic Cannabinoids, by Sales Channel USD Million (2021-2026)
  • Table 130. Rest of South America Synthetic Cannabinoids, by Type USD Million (2021-2026)
  • Table 131. Rest of South America Synthetic Cannabinoids, by Application USD Million (2021-2026)
  • Table 132. Rest of South America Synthetic Cannabinoids, by Sales Channel USD Million (2021-2026)
  • Table 133. Asia Pacific Synthetic Cannabinoids, by Country USD Million (2021-2026)
  • Table 134. Asia Pacific Synthetic Cannabinoids, by Type USD Million (2021-2026)
  • Table 135. Asia Pacific Synthetic Cannabinoids, by Application USD Million (2021-2026)
  • Table 136. Asia Pacific Synthetic Cannabinoids, by Sales Channel USD Million (2021-2026)
  • Table 137. China Synthetic Cannabinoids, by Type USD Million (2021-2026)
  • Table 138. China Synthetic Cannabinoids, by Application USD Million (2021-2026)
  • Table 139. China Synthetic Cannabinoids, by Sales Channel USD Million (2021-2026)
  • Table 140. Japan Synthetic Cannabinoids, by Type USD Million (2021-2026)
  • Table 141. Japan Synthetic Cannabinoids, by Application USD Million (2021-2026)
  • Table 142. Japan Synthetic Cannabinoids, by Sales Channel USD Million (2021-2026)
  • Table 143. India Synthetic Cannabinoids, by Type USD Million (2021-2026)
  • Table 144. India Synthetic Cannabinoids, by Application USD Million (2021-2026)
  • Table 145. India Synthetic Cannabinoids, by Sales Channel USD Million (2021-2026)
  • Table 146. South Korea Synthetic Cannabinoids, by Type USD Million (2021-2026)
  • Table 147. South Korea Synthetic Cannabinoids, by Application USD Million (2021-2026)
  • Table 148. South Korea Synthetic Cannabinoids, by Sales Channel USD Million (2021-2026)
  • Table 149. Taiwan Synthetic Cannabinoids, by Type USD Million (2021-2026)
  • Table 150. Taiwan Synthetic Cannabinoids, by Application USD Million (2021-2026)
  • Table 151. Taiwan Synthetic Cannabinoids, by Sales Channel USD Million (2021-2026)
  • Table 152. Australia Synthetic Cannabinoids, by Type USD Million (2021-2026)
  • Table 153. Australia Synthetic Cannabinoids, by Application USD Million (2021-2026)
  • Table 154. Australia Synthetic Cannabinoids, by Sales Channel USD Million (2021-2026)
  • Table 155. Rest of Asia-Pacific Synthetic Cannabinoids, by Type USD Million (2021-2026)
  • Table 156. Rest of Asia-Pacific Synthetic Cannabinoids, by Application USD Million (2021-2026)
  • Table 157. Rest of Asia-Pacific Synthetic Cannabinoids, by Sales Channel USD Million (2021-2026)
  • Table 158. Europe Synthetic Cannabinoids, by Country USD Million (2021-2026)
  • Table 159. Europe Synthetic Cannabinoids, by Type USD Million (2021-2026)
  • Table 160. Europe Synthetic Cannabinoids, by Application USD Million (2021-2026)
  • Table 161. Europe Synthetic Cannabinoids, by Sales Channel USD Million (2021-2026)
  • Table 162. Germany Synthetic Cannabinoids, by Type USD Million (2021-2026)
  • Table 163. Germany Synthetic Cannabinoids, by Application USD Million (2021-2026)
  • Table 164. Germany Synthetic Cannabinoids, by Sales Channel USD Million (2021-2026)
  • Table 165. France Synthetic Cannabinoids, by Type USD Million (2021-2026)
  • Table 166. France Synthetic Cannabinoids, by Application USD Million (2021-2026)
  • Table 167. France Synthetic Cannabinoids, by Sales Channel USD Million (2021-2026)
  • Table 168. Italy Synthetic Cannabinoids, by Type USD Million (2021-2026)
  • Table 169. Italy Synthetic Cannabinoids, by Application USD Million (2021-2026)
  • Table 170. Italy Synthetic Cannabinoids, by Sales Channel USD Million (2021-2026)
  • Table 171. United Kingdom Synthetic Cannabinoids, by Type USD Million (2021-2026)
  • Table 172. United Kingdom Synthetic Cannabinoids, by Application USD Million (2021-2026)
  • Table 173. United Kingdom Synthetic Cannabinoids, by Sales Channel USD Million (2021-2026)
  • Table 174. Netherlands Synthetic Cannabinoids, by Type USD Million (2021-2026)
  • Table 175. Netherlands Synthetic Cannabinoids, by Application USD Million (2021-2026)
  • Table 176. Netherlands Synthetic Cannabinoids, by Sales Channel USD Million (2021-2026)
  • Table 177. Rest of Europe Synthetic Cannabinoids, by Type USD Million (2021-2026)
  • Table 178. Rest of Europe Synthetic Cannabinoids, by Application USD Million (2021-2026)
  • Table 179. Rest of Europe Synthetic Cannabinoids, by Sales Channel USD Million (2021-2026)
  • Table 180. MEA Synthetic Cannabinoids, by Country USD Million (2021-2026)
  • Table 181. MEA Synthetic Cannabinoids, by Type USD Million (2021-2026)
  • Table 182. MEA Synthetic Cannabinoids, by Application USD Million (2021-2026)
  • Table 183. MEA Synthetic Cannabinoids, by Sales Channel USD Million (2021-2026)
  • Table 184. Middle East Synthetic Cannabinoids, by Type USD Million (2021-2026)
  • Table 185. Middle East Synthetic Cannabinoids, by Application USD Million (2021-2026)
  • Table 186. Middle East Synthetic Cannabinoids, by Sales Channel USD Million (2021-2026)
  • Table 187. Africa Synthetic Cannabinoids, by Type USD Million (2021-2026)
  • Table 188. Africa Synthetic Cannabinoids, by Application USD Million (2021-2026)
  • Table 189. Africa Synthetic Cannabinoids, by Sales Channel USD Million (2021-2026)
  • Table 190. North America Synthetic Cannabinoids, by Country USD Million (2021-2026)
  • Table 191. North America Synthetic Cannabinoids, by Type USD Million (2021-2026)
  • Table 192. North America Synthetic Cannabinoids, by Application USD Million (2021-2026)
  • Table 193. North America Synthetic Cannabinoids, by Sales Channel USD Million (2021-2026)
  • Table 194. United States Synthetic Cannabinoids, by Type USD Million (2021-2026)
  • Table 195. United States Synthetic Cannabinoids, by Application USD Million (2021-2026)
  • Table 196. United States Synthetic Cannabinoids, by Sales Channel USD Million (2021-2026)
  • Table 197. Canada Synthetic Cannabinoids, by Type USD Million (2021-2026)
  • Table 198. Canada Synthetic Cannabinoids, by Application USD Million (2021-2026)
  • Table 199. Canada Synthetic Cannabinoids, by Sales Channel USD Million (2021-2026)
  • Table 200. Mexico Synthetic Cannabinoids, by Type USD Million (2021-2026)
  • Table 201. Mexico Synthetic Cannabinoids, by Application USD Million (2021-2026)
  • Table 202. Mexico Synthetic Cannabinoids, by Sales Channel USD Million (2021-2026)
  • Table 203. Research Programs/Design for This Report
  • Table 204. Key Data Information from Secondary Sources
  • Table 205. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Synthetic Cannabinoids: by Type USD Million (2015-2020)
  • Figure 5. Global Synthetic Cannabinoids: by Application USD Million (2015-2020)
  • Figure 6. Global Synthetic Cannabinoids: by Sales Channel USD Million (2015-2020)
  • Figure 7. South America Synthetic Cannabinoids Share (%), by Country
  • Figure 8. Asia Pacific Synthetic Cannabinoids Share (%), by Country
  • Figure 9. Europe Synthetic Cannabinoids Share (%), by Country
  • Figure 10. MEA Synthetic Cannabinoids Share (%), by Country
  • Figure 11. North America Synthetic Cannabinoids Share (%), by Country
  • Figure 12. Global Synthetic Cannabinoids share by Players 2020 (%)
  • Figure 13. Global Synthetic Cannabinoids share by Players (Top 3) 2020(%)
  • Figure 14. Global Synthetic Cannabinoids share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Noramco (United States) Revenue, Net Income and Gross profit
  • Figure 17. Noramco (United States) Revenue: by Geography 2020
  • Figure 18. Lygos (Librede) (United States) Revenue, Net Income and Gross profit
  • Figure 19. Lygos (Librede) (United States) Revenue: by Geography 2020
  • Figure 20. CV Sciences (United States) Revenue, Net Income and Gross profit
  • Figure 21. CV Sciences (United States) Revenue: by Geography 2020
  • Figure 22. Hyasynth Biologicals (Canada) Revenue, Net Income and Gross profit
  • Figure 23. Hyasynth Biologicals (Canada) Revenue: by Geography 2020
  • Figure 24. Renew Biopharma (United States) Revenue, Net Income and Gross profit
  • Figure 25. Renew Biopharma (United States) Revenue: by Geography 2020
  • Figure 26. CannBioRx Life Sciences (United States) Revenue, Net Income and Gross profit
  • Figure 27. CannBioRx Life Sciences (United States) Revenue: by Geography 2020
  • Figure 28. Ginkgo Bioworks (United States) Revenue, Net Income and Gross profit
  • Figure 29. Ginkgo Bioworks (United States) Revenue: by Geography 2020
  • Figure 30. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. AbbVie Inc. (United States) Revenue: by Geography 2020
  • Figure 32. GW Pharmaceuticals plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. GW Pharmaceuticals plc (United Kingdom) Revenue: by Geography 2020
  • Figure 34. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Mylan N.V. (United States) Revenue: by Geography 2020
  • Figure 36. Global Synthetic Cannabinoids: by Type USD Million (2021-2026)
  • Figure 37. Global Synthetic Cannabinoids: by Application USD Million (2021-2026)
  • Figure 38. Global Synthetic Cannabinoids: by Sales Channel USD Million (2021-2026)
  • Figure 39. South America Synthetic Cannabinoids Share (%), by Country
  • Figure 40. Asia Pacific Synthetic Cannabinoids Share (%), by Country
  • Figure 41. Europe Synthetic Cannabinoids Share (%), by Country
  • Figure 42. MEA Synthetic Cannabinoids Share (%), by Country
  • Figure 43. North America Synthetic Cannabinoids Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Noramco (United States)
  • Lygos (Librede) (United States)
  • CV Sciences (United States)
  • Hyasynth Biologicals (Canada)
  • Renew Biopharma (United States)
  • CannBioRx Life Sciences (United States)
  • Ginkgo Bioworks (United States)
  • AbbVie Inc. (United States)
  • GW Pharmaceuticals plc (United Kingdom)
  • Mylan N.V. (United States)
Additional players considered in the study are as follows:
Isodiol International Inc (Canada) , CURE Pharmaceutical (United States) , Zynerba Pharmaceuticals, Inc. (United States) , Aphios Corporation (United Kingdom) , Botanix Pharmaceuticals (Australia) , Insys Therapeutics, Inc (United States)
Select User Access Type

Key Highlights of Report


Mar 2021 242 Pages 50 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Synthetic Cannabinoids Market Quantitative research analysis
Global Synthetic Cannabinoids Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Global Synthetic Cannabinoids market is expected to see a growth of % during projected year 2020 to 2026.
The prominent players of Global Synthetic Cannabinoids market are Noramco (United States), Lygos (Librede) (United States), CV Sciences (United States), Hyasynth Biologicals (Canada), Renew Biopharma (United States), CannBioRx Life Sciences (United States), Ginkgo Bioworks (United States), AbbVie Inc. (United States), GW Pharmaceuticals plc (United Kingdom) and Mylan N.V. (United States), to name a few.
In this highly competitive & fast evolving Synthetic Cannabinoids industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.

Know More About Global Synthetic Cannabinoids Market Report?

Have a Query? Click Here

Other Related Reports

Methyl Glucose Comprehensive Study by Type (Esters, Polyethers, Esters and Polyethers), Application (Cosmetic, Non-cosmetic, Others), Sales Channel (Direct, Indirect) Players and Region - Global Mark...
$ 3500
Antifreeze Agents Comprehensive Study by Type (Propylene glycol, Glycerin, Ethylene glycol, Calcium chloride, Others), Application (Automotive and transportation, Oil and gas, Electrical and electron...
$ 3650
Bio-based Epoxy Resins Comprehensive Study by Type (Vegetable Glycerol, Canola, Hemp, Soybean oil, Plant Oils, Others), Application (Coatings, Electronics, Adhesives, Composites, Others) Players and ...
$ 3500
Heavy Fuel Oil Comprehensive Study by Type (Low, Medium, High), Application (Industrial (Oil and Gas, Mining, Shipping and Contracting and Other), Non- Industrial (Residential, Commercial and Institu...
$ 3500
Furniture Films And Foils Comprehensive Study by Application (Furniture, Doors & Windows), Material (Polyvinyl Chloride, Polyester, Polypropylene, Vinyl), End User (Residential, Commercial, Institut...
$ 3500
Alkylphenol Ethoxylates Comprehensive Study by Type (Industrial Grade, Non-Industrial Grade), Application (Emulsion Polymerization, Detergents, Lubricants and Oil Additives, Surfactant, Others), Indu...
$ 3750